WO2000070099A3 - Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives - Google Patents
Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives Download PDFInfo
- Publication number
- WO2000070099A3 WO2000070099A3 PCT/US2000/013951 US0013951W WO0070099A3 WO 2000070099 A3 WO2000070099 A3 WO 2000070099A3 US 0013951 W US0013951 W US 0013951W WO 0070099 A3 WO0070099 A3 WO 0070099A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- contactin
- present
- neurodegenerative disease
- compounds
- compositions
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 5
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 5
- 210000004556 brain Anatomy 0.000 title 1
- 230000009274 differential gene expression Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 7
- 102000018361 Contactin Human genes 0.000 abstract 6
- 108060003955 Contactin Proteins 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002371212A CA2371212A1 (fr) | 1999-05-19 | 2000-05-19 | Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives |
JP2000618504A JP2003504007A (ja) | 1999-05-19 | 2000-05-19 | 神経変性性疾患における脳の特異的な領域での異なる遺伝子発現 |
AU51503/00A AU5150300A (en) | 1999-05-19 | 2000-05-19 | Differential gene expression in specific regions of the brain in neurodegenerative diseases |
EP00936142A EP1208228A2 (fr) | 1999-05-19 | 2000-05-19 | Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13479099P | 1999-05-19 | 1999-05-19 | |
US60/134,790 | 1999-05-19 | ||
US57461300A | 2000-05-18 | 2000-05-18 | |
US09/574,613 | 2000-05-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000070099A2 WO2000070099A2 (fr) | 2000-11-23 |
WO2000070099A3 true WO2000070099A3 (fr) | 2002-04-04 |
Family
ID=26832668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/013951 WO2000070099A2 (fr) | 1999-05-19 | 2000-05-19 | Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1208228A2 (fr) |
JP (1) | JP2003504007A (fr) |
AU (1) | AU5150300A (fr) |
CA (1) | CA2371212A1 (fr) |
WO (1) | WO2000070099A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001069261A2 (fr) * | 2000-03-15 | 2001-09-20 | Oxford Glycosciences (Uk) Ltd. | Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire |
AU2002239531A1 (en) * | 2000-11-08 | 2002-05-27 | Mitokor | Differential gene expression in specific regions of the brain in neurodegenerative diseases |
ATE394115T1 (de) | 2001-02-27 | 2008-05-15 | Brni Neurosciences Inst | Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung |
WO2003023056A2 (fr) * | 2001-09-12 | 2003-03-20 | F. Hoffmann-La Roche Ag | Marqueurs specifiques a la sclerose en plaques |
EP1497661B1 (fr) * | 2002-04-24 | 2009-11-25 | EVOTEC Neurosciences GmbH | Utilisation a des fins diagnostiques du gene et de la proteine ensadine-0477 pour le traitement de maladies neurodegeneratives |
EP1587960A2 (fr) * | 2003-01-30 | 2005-10-26 | Research Development Foundation | Procedes et compositions d'analyse de l'expression genique liee a la mitochondrie |
CA2582270A1 (fr) * | 2004-11-15 | 2006-05-26 | Blanchette Rockefeller Neurosciences Institute | Anomalies de la phosphatase 2a (pp2a) pour le diagnostic et le traitement de la maladie d'alzheimer |
US20090029873A1 (en) | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
US8252540B2 (en) | 2007-08-03 | 2012-08-28 | Keio University | Drug delivery system toward demyelinating lesion and biochemical marker of demyelinating lesion |
US8822166B2 (en) | 2008-07-28 | 2014-09-02 | Blanchette Rockefeller Neurosciences Institute | Stimulus-elicited genomic profile markers of alzheimer's disease |
US8163800B2 (en) | 2008-07-28 | 2012-04-24 | Blanchette Rockefeller Neurosciences Institute | PKC-activating compounds for the treatment of neurodegenerative diseases |
WO2011041761A1 (fr) | 2009-10-02 | 2011-04-07 | Blanchette Rockefeller Neurosciences Institute | Profils de croissance de fibroblastes pour le diagnostic de la maladie d'alzheimer |
WO2013071281A1 (fr) | 2011-11-13 | 2013-05-16 | Blanchette Rockefeller Neurosciences Institute | Esters de dcpla et méthodes de traitement les utilisant |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035373A2 (fr) * | 1994-06-10 | 1995-12-28 | La Jolla Cancer Research Foundation | Molecules d'acide nucleique codant la contactine humaine |
WO1997015690A1 (fr) * | 1995-10-24 | 1997-05-01 | Curagen Corporation | Procede et dispositif d'identification, de classification ou de denombrement de sequences d'adn dans un echantillon sans sequençage |
US5739289A (en) * | 1993-03-26 | 1998-04-14 | Becton, Dickinson And Company | Monoclonal antibody to human cell adhesion molecule |
WO1998049342A1 (fr) * | 1997-04-30 | 1998-11-05 | Forskningsparken I Ås As | Procede servant a preparer un type standard de produit de transcription genetique de diagnostic |
US5888498A (en) * | 1995-03-03 | 1999-03-30 | Mitokor | Cellular and animal models for diseases associated with mitochondrial defects |
-
2000
- 2000-05-19 EP EP00936142A patent/EP1208228A2/fr not_active Withdrawn
- 2000-05-19 AU AU51503/00A patent/AU5150300A/en not_active Abandoned
- 2000-05-19 CA CA002371212A patent/CA2371212A1/fr not_active Abandoned
- 2000-05-19 WO PCT/US2000/013951 patent/WO2000070099A2/fr not_active Application Discontinuation
- 2000-05-19 JP JP2000618504A patent/JP2003504007A/ja not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739289A (en) * | 1993-03-26 | 1998-04-14 | Becton, Dickinson And Company | Monoclonal antibody to human cell adhesion molecule |
WO1995035373A2 (fr) * | 1994-06-10 | 1995-12-28 | La Jolla Cancer Research Foundation | Molecules d'acide nucleique codant la contactine humaine |
US5888498A (en) * | 1995-03-03 | 1999-03-30 | Mitokor | Cellular and animal models for diseases associated with mitochondrial defects |
WO1997015690A1 (fr) * | 1995-10-24 | 1997-05-01 | Curagen Corporation | Procede et dispositif d'identification, de classification ou de denombrement de sequences d'adn dans un echantillon sans sequençage |
WO1998049342A1 (fr) * | 1997-04-30 | 1998-11-05 | Forskningsparken I Ås As | Procede servant a preparer un type standard de produit de transcription genetique de diagnostic |
Non-Patent Citations (2)
Title |
---|
PLAGGE A ET AL: "The gene of the neural cell recognition molecule F11: conserved exon-intron arrangement in genes of neural members of the immunoglobulin superfamily", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 192, no. 2, 1997, pages 215 - 225, XP004081714, ISSN: 0378-1119 * |
SHIMAZAKI K ET AL: "Age-related decline of f3/contactin in rat hippocampus", NEUROSCIENCE LETTERS, vol. 245, no. 2, 1998, pages 117 - 20, XP001024403 * |
Also Published As
Publication number | Publication date |
---|---|
AU5150300A (en) | 2000-12-05 |
JP2003504007A (ja) | 2003-02-04 |
WO2000070099A2 (fr) | 2000-11-23 |
EP1208228A2 (fr) | 2002-05-29 |
CA2371212A1 (fr) | 2000-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Condliffe et al. | Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain | |
Nakano et al. | Homologous recombination but not nucleotide excision repair plays a pivotal role in tolerance of DNA-protein cross-links in mammalian cells | |
Haghdoost et al. | The nucleotide pool is a significant target for oxidative stress | |
Zhu et al. | MicroRNA-494 improves functional recovery and inhibits apoptosis by modulating PTEN/AKT/mTOR pathway in rats after spinal cord injury | |
Vannini et al. | Effects of a complex mixture of therapeutic drugs on unicellular algae Pseudokirchneriella subcapitata | |
Goto et al. | Yeast DNA topoisomerase II. An ATP-dependent type II topoisomerase that catalyzes the catenation, decatenation, unknotting, and relaxation of double-stranded DNA rings. | |
Phay et al. | Analysis of piRNA-like small non-coding RNAs present in axons of adult sensory neurons | |
US10550426B2 (en) | Method for detecting methylated DNA | |
WO2000070099A3 (fr) | Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives | |
CN110791560B (zh) | 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物 | |
Kumar et al. | Tet1 oxidase regulates neuronal gene transcription, active DNA hydroxymethylation, object location memory, and threat recognition memory | |
Liu et al. | PARP-1 enhances the mismatch-dependence of 5′-directed excision in human mismatch repair in vitro | |
WO2006096737A3 (fr) | Cible diagnostique et therapeutique pour degenerescence maculaire | |
Sarasin et al. | New insights for understanding the transcription-coupled repair pathway | |
Rezende et al. | Knock out of the NADPH oxidase Nox4 has no impact on life span in mice | |
Guo et al. | Genome-wide antagonism between 5-hydroxymethylcytosine and DNA methylation in the adult mouse brain | |
WO2010011283A3 (fr) | Composés à base de fus/tls et méthodes de diagnostic, traitement et prévention d'une sclérose latérale amyotrophique et de maladies des motoneurones apparentées | |
de Melo et al. | XPC deficiency is related to APE1 and OGG1 expression and function | |
Mukai et al. | Recombinant mammalian tubulin polyglutamylase TTLL7 performs both initiation and elongation of polyglutamylation on β-tubulin through a random sequential pathway | |
AU2016282350A1 (en) | Targeted enrichment of long nucleotide sequences using microfluidic partitioning | |
US11359245B2 (en) | Method for determining decrease in functions of hippocampus by using correlation between micro RNA and NMDA receptor, method for inhibiting decrease in functions, and method for screening for inhibitors of decrease in functions | |
JP2010535501A (ja) | チオプリン薬抵抗性およびチオプリン薬不耐性のリスクがある個体を同定する方法 | |
Rybin et al. | Emerging technologies for genome-wide profiling of DNA breakage | |
Trotzier et al. | Phosphorylation of ICBP90 by protein kinase A enhances topoisomerase IIα expression | |
Vindry et al. | A homozygous mutation in the human selenocysteine tRNA gene impairs UGA recoding activity and selenoproteome regulation by selenium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2371212 Country of ref document: CA Ref country code: CA Ref document number: 2371212 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 51503/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 618504 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000936142 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWP | Wipo information: published in national office |
Ref document number: 2000936142 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000936142 Country of ref document: EP |